Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

AlzeCure Pharma

1.84 SEK

-1.87 %

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.87 %
-3.42 %
-8.25 %
-12.62 %
-31.78 %
-40.39 %
-52.92 %
-72.67 %
-80.62 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
210.87M SEK
Turnover
50.11K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/5
2026

Interim report Q1'26

14/5
2026

General meeting '26

26/8
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Third party research3/5/2026, 10:56 AM

AlzeCure Pharma: I väntan på nästa fas - Analysguiden

Alzecure förbereder sedan en länge tid en fas 2a-studie med bolagets innovativa projekt ACD856, en så kallad tropomyosin-receptor kinas-modulator, som verkar kognitionshöjande. Möjliga populationer att behandla finns inom Alzheimer- och depressionsomr...

AlzeCure Pharma
Press release3/5/2026, 10:35 AM

Analysguiden: ANALYS: AlzeCure Pharma: I väntan på nästa fas

AlzeCure Pharma
Press release3/4/2026, 9:00 AM

AlzeCure Pharma presenterar på Stora Aktiedagarna i Stockholm 11 mars

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/4/2026, 9:00 AM

AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on March 11

AlzeCure Pharma
Press release3/3/2026, 9:49 AM

Redeye: AlzeCure Pharma (Q4 2025): Focused execution across core development programmes

AlzeCure Pharma
Regulatory press release2/26/2026, 7:00 AM

AlzeCure offentliggör bokslutskommuniké för januari – december 2025

AlzeCure Pharma
Regulatory press release2/26/2026, 7:00 AM

AlzeCure publishes its Year-end report for January – December 2025

AlzeCure Pharma
Press release2/24/2026, 11:30 AM

Smärtprojektet ACD440 beviljas särläkemedelsstatus i EU

AlzeCure Pharma
Press release2/24/2026, 11:30 AM

Pain project ACD440 granted orphan drug status in the EU

AlzeCure Pharma
Press release2/3/2026, 9:00 AM

AlzeCure abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026

AlzeCure Pharma
Press release2/3/2026, 9:00 AM

AlzeCure abstract om NeuroRestore ACD856 accepterat på Alzheimer-konferensen AP/PD 2026

AlzeCure Pharma
Press release2/2/2026, 12:00 PM

AlzeCure Pharma utvalt att presentera på Bio-Neuroscience-konferensen i Amsterdam

AlzeCure Pharma
Press release2/2/2026, 12:00 PM

AlzeCure Pharma selected to present at the Bio-Neuroscience conference in Amsterdam

AlzeCure Pharma
Press release12/3/2025, 9:00 AM

AlzeCure får utbetalning av EU-anslag för klinisk fas 2-studie med NeuroRestore ACD856 för Alzheimers sjukdom

AlzeCure Pharma
Press release12/3/2025, 9:00 AM

AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer's disease

AlzeCure Pharma
Third party research11/17/2025, 10:17 AM

AlzeCure Pharma: Breddar ACD856-program - Analysguiden

Alzecure drar i gång en avslutande fas 1-studie med ACD-856 för att dokumentera högre doser jämfört med doseringen i den senaste studien. Denna breddning av programmet kan öppna för behandling av bland annat svår depression. Vi ser den nya studien som...

AlzeCure Pharma
Press release11/17/2025, 10:15 AM

Analysguiden: ANALYS AlzeCure Pharma: Breddar ACD856-program

AlzeCure Pharma
Press release11/14/2025, 11:35 AM

Redeye: AlzeCure Pharma (Q3 Review) - Clinical phase IIa study in focus

AlzeCure Pharma
Regulatory press release11/11/2025, 7:00 AM

AlzeCure publishes its interim report for January – September 2025

AlzeCure Pharma
Regulatory press release11/11/2025, 7:00 AM

AlzeCure offentliggör delårsrapport för januari – september 2025

AlzeCure Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.